8CN3 image
Entry Detail
PDB ID:
8CN3
Keywords:
Title:
hDLG1-PDZ2 in complex with a TAX1 peptide from HTLV-1
Biological Source:
PDB Version:
Deposition Date:
2023-02-21
Release Date:
2023-08-02
Method Details:
Experimental Method:
Resolution:
2.71 Å
R-Value Free:
0.25
R-Value Work:
0.18
R-Value Observed:
0.19
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Disks large homolog 1
Chain IDs:A
Chain Length:117
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Disks large homolog 1
Chain IDs:B
Chain Length:117
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:GLU-THR-GLU-VAL
Chain IDs:C, D
Chain Length:4
Number of Molecules:2
Biological Source:Human T-cell lymphotrophic virus type 1 (strain ATK)
Primary Citation
Identification of small molecule antivirals against HTLV-1 by targeting the hDLG1-Tax-1 protein-protein interaction.
Antiviral Res. 217 105675 105675 (2023)
PMID: 37481039 DOI: 10.1016/j.antiviral.2023.105675

Abstact

Human T-cell leukemia virus type-1 (HTLV-1) is the first pathogenic retrovirus discovered in human. Although HTLV-1-induced diseases are well-characterized and linked to the encoded Tax-1 oncoprotein, there is currently no strategy to target Tax-1 functions with small molecules. Here, we analyzed the binding of Tax-1 to the human homolog of the drosophila discs large tumor suppressor (hDLG1/SAP97), a multi-domain scaffolding protein involved in Tax-1-transformation ability. We have solved the structures of the PDZ binding motif (PBM) of Tax-1 in complex with the PDZ1 and PDZ2 domains of hDLG1 and assessed the binding of 10 million molecules by virtual screening. Among the 19 experimentally confirmed compounds, one systematically inhibited the Tax-1-hDLG1 interaction in different biophysical and cellular assays, as well as HTLV-1 cell-to-cell transmission in a T-cell model. Thus, our work demonstrates that interactions involving Tax-1 PDZ-domains are amenable to small-molecule inhibition, which provides a framework for the design of targeted therapies for HTLV-1-induced diseases.

Legend

Protein

Chemical

Disease

Primary Citation of related structures